Coherus Oncology (CHRS) Minority Interest (2014 - 2018)

Coherus Oncology (CHRS) has 5 years of Minority Interest data on file, last reported at -$1.3 million in Q2 2018.

• For the quarter ending Q2 2018, Minority Interest fell 4.52% year-over-year to -$1.3 million; the trailing twelve-month figure through Jun 2018 stood at -$1.3 million (down 4.52% YoY), and the FY2017 full-year result was -$1.3 million, down 9.89% from the prior year.
• Minority Interest retreated to -$1.3 million in Q2 2018, from -$1.3 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of -$44000.0 in Q4 2014 to a low of -$1.3 million in Q2 2018.
• A 5-year average of -$872250.0 and a median of -$1.1 million in 2016 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest sank 1540.91% in 2015 and decreased 4.52% in 2018, its largest moves.
• Tracing CHRS's Minority Interest over 5 years: stood at -$44000.0 in 2014, then sank by 1540.91% to -$722000.0 in 2015, then plunged by 62.47% to -$1.2 million in 2016, then declined by 9.89% to -$1.3 million in 2017, then fell by 4.03% to -$1.3 million in 2018.
• Business Quant data shows CHRS's Minority Interest at -$1.3 million in Q2 2018, -$1.3 million in Q1 2018, and -$1.3 million in Q4 2017.